Behavioral
New Vision Therapy PLLC
New Vision Therapy PLLC was paid $1.33M by Medicaid between Jan 2018 and Dec 2024, across 15 billing codes. Its largest line is 90837, psychotherapy session, about an hour — 39% of everything it billed.
33Billing provider infoNEW VISION THERAPY PLLC
GREENSBORO, NC 27403
GREENSBORO, NC 27403
33aNPI1033666888assigned 09/08/2016
33bProvider typeAddiction (Substance Use Disorder) Counselor
28Total paid$1.33M
24GClaims26,110
24DCodes billed15
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Addiction (Substance Use Disorder) Counselor providers in North Carolina
Rank by total paid#48 of 222
Median peer was paid$168K
This provider vs. median7.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,358 | $80K | |
| 2019 | 3,654 | $130K | |
| 2020 | 3,418 | $94K | |
| 2021 | 3,482 | $142K | |
| 2022 | 4,447 | $275K | |
| 2023 | 4,260 | $275K | |
| 2024incomplete | 4,491 | $335K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 39% | 7,048 | 1,825 | $516K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 18% | 7,988 | 2,306 | $240K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 9.9% | 3,193 | 1,324 | $132K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 6.3% | 514 | 254 | $84K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.0% | 805 | 517 | $79K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.9% | 1,304 | 711 | $79K |
| 99401 | 5.0% | 2,348 | 1,259 | $67K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.7% | 990 | 568 | $62K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.4% | 249 | 188 | $32K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.7% | 349 | 213 | $22K |
| 98968 | <1% | 370 | 170 | $12K | |
| 99441 | <1% | 490 | 88 | $2K |
3 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 428 | $2K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 13 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 21 | $853.77 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSANDIFER, MARVIN (CEO)